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Abstract
Background. Chronotherapy is an innovative approach to improving survival through timed delivery of anti-cancer
treatments according to patient daily rhythms. Temozolomide (TMZ) is a standard-of-care chemotherapeutic agent
for glioblastoma (GBM). Whether timing of TMZ administration affects GBM patient outcome has not previously
been studied. We sought to evaluate maintenance TMZ chronotherapy on GBM patient survival.
Methods. This retrospective study reviewed patients with newly diagnosed GBM from January 1, 2010 to December
31, 2018 at Washington University School of Medicine who had surgery, chemoradiation, and were prescribed
TMZ to be taken in the morning or evening. The Kaplan–Meier method and Cox regression model were used for
overall survival (OS) analyses. The propensity score method accounted for potential observational study biases.
The restricted mean survival time (RMST) method was performed where the proportional hazard assumption was
violated.
Results. We analyzed 166 eligible GBM patients with a median follow-up of 5.07 years. Patients taking morning
TMZ exhibited longer OS compared to evening (median OS, 95% confidence interval [CI] = 1.43, 1.12–1.92 vs
1.13, 0.84–1.58 years) with a significant year 1 RMST difference (−0.09, 95% CI: −0.16 to −0.018). Among MGMTmethylated patients, median OS was 6 months longer for AM patients with significant RMST differences at years 1
(−0.13, 95% CI = −0.24 to −0.019) to 2.5 (−0.43, 95% CI = −0.84 to −0.028). Superiority of morning TMZ at years 1, 2,
and 5 (all P < .05) among all patients was supported by RMST difference regression after adjusting for confounders.
Conclusions. Our study presents preliminary evidence for the benefit of TMZ chronotherapy to GBM patient survival. This impact is more pronounced in MGMT-methylated patients.

Key Points
• Morning temozolomide administration may improve survival for patients with
glioblastoma.
• Morning TMZ demonstrates greater benefit in MGMT-methylated patients.
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Importance of the Study

Glioblastoma (GBM), the most common adult primary brain
tumor,1 has a dismal prognosis. Standard of care treatment
of GBM patients involves maximal safe surgical resection,
followed by concurrent radiotherapy with temozolomide
(TMZ), and maintenance treatment with TMZ thereafter.
After several decades of clinical trials involving multiple
chemotherapeutics, the addition of TMZ to surgery and radiation therapy was demonstrated to extend survival by
2.5 months.2,3 TMZ received FDA approval for GBM based
on this modest survival improvement in 2005. In 2011,
tumor-treating fields (TTF) were approved for GBM based
on evidence for progression-free survival improvement by
2.7 months and overall survival by 4.9 months, when added
to TMZ.4 Unfortunately, the 5-year survival rate for adults
with GBM remains low at 5%–14%3–6 and further improvements in front-line treatments are necessary.
Circadian medicine considers daily rhythms in drug
metabolism and cancer cell treatment response.7–9 Daily
rhythms in physiology and behavior depend upon cellular
circadian clocks in the brain and body. A master circadian
pacemaker in the hypothalamic suprachiasmatic nucleus
regulates peripheral functions through neural, endocrine,
metabolic, and behavioral outputs including sleep–wake
and feeding–fasting.10 These signals act on nearly all cells
to synchronize their intrinsic daily rhythms. The core clock
mechanism, discovery of which was awarded the Nobel
Prize in 2017, drives daily rhythms in up to 50% of a cell’s
transcriptome depending on the cell type11,12 and entrains
to environmental timing cues like the local light cycle.
Daily rhythms in metabolism,9 cell cycle regulation,13 and
DNA repair14,15 likely modulate the efficacy of cancer treatments.16 Two recent studies highlighted potential benefits
of treatment with drugs that target the circadian mechanism in glioblastoma. They found that chronic agonists of
REV-ERB and CRY could perform as well as TMZ in GBM
models implanted in mice.17,18 As an alternative approach,
chronotherapy has been studied for its potential to improve treatment outcomes through optimizing the timed
delivery of medication according to the patients’ circadian rhythms. Recent studies have demonstrated circadian
regulation of the p38 mitogen-activated protein kinase
(MAPK) signal transduction pathway in Neurospora19 and
in glioma cells’ response to a p38 MAPK inhibitor.20 We previously published that patient-derived and murine-model
GBM cells exhibited circadian transcription of the clock
genes, Bmal1 and Period2 (Per2). Critically, murine GBM
cells showed more than 3-fold greater DNA damage, activation of the apoptotic pathway and cell death following
TMZ treatment at the peak of Bmal1 expression compared
to at its daily minimum of expression.16 Furthermore, the

and prolongs survival. This dosing modification can be quickly adopted in clinical practice.
This study lays the foundation for larger scale
chronomedicine trials for brain cancer.

expression of the protein responsible for repair of DNA
double-strand breaks induced by TMZ, O-6-MethylguanineDNA Methyltransferase (MGMT), oscillates with time of
day.21–23 Sensitivity of cell cycle checkpoint mediated apoptosis has also been shown to change based on time of day
via an interaction with 2 clock genes, Per1 and Per3.14,24 It is
not yet known if clock gene expression delimits an optimal
therapeutic time window for TMZ treatment.
A recent meta-analysis found that, of the 50 most prescribed drugs, only 4 have a recommended time of administration, over 56% of drugs target proteins that exhibit
circadian variation in expression, and over 75% of 106
clinical trials involving 70 drugs found results varied with
time of day.7 Chronotherapy, treatment at the optimal time
of day, can increase tumor cell death and reduce side effects,14 allowing for longer or elevated dosing. Despite the
success of chronotherapy in pediatric acute lymphoblastic
leukemia,25,26 colorectal cancer,27–29 ovarian cancer, and
some gynecological and genitourinary cancers,30 timing
of drug administration is rarely accounted for in clinical trials and has not been investigated in the context of
brain cancer.
TMZ readily crosses the blood brain barrier and has
a short half-life.31 This makes TMZ an ideal and novel
chronotherapeutic drug. The effect of TMZ chronotherapy
in GBM has not previously been investigated. Based on
findings in preclinical studies and the results of chronotherapy studies in other cancer types, we initiated a retrospective analysis of glioblastoma patients to compare
the efficacy of maintenance TMZ treatment in the morning
versus in the evening.

Methods
Patients
A total of 498 patients who were diagnosed with glioblastoma from January 1, 2010 to December 31, 2018 at
Washington University School of Medicine (WUSM) were
screened for inclusion in the study. GBM patients seen at
WUSM during this period received radiation therapy (RT)
with concurrent TMZ in the morning. Approximately 4
weeks post-concurrent chemoradiation, maintenance TMZ
was initiated as morning or evening dosing per provider
preference. Following screening (see flow chart of inclusion/exclusion criteria in Supplementary Figure 1), 180
patient records were deemed evaluable for this study. For
the maintenance TMZ in this cohort, 3 (GA, GL, DT) of the 4
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The primary patient outcome is overall survival (OS), calculated as the time interval from the start date of maintenance TMZ (post-chemoradiation) to the date of death if a
patient died or to the date of last contact. Patient characteristics were summarized using descriptive statistics, count,
and percentages for categorical characteristics and median and interquartile range (IQR) for quantitative characteristics, overall and by TMZ timing, while the distribution
difference by TMZ timing was assessed by Fisher’s exact
test and Wilcoxon rank sum test for categorical and quantitative characteristics, respectively. The Kaplan–Meier
(KM) method was applied to estimate empirical survival
probability to report median OS estimates with 95% confidence interval (CI) and the KM curves were generated
for visualization. The log-rank test was used to compare
the survival difference between patient groups. The Cox
proportional hazard regression model was applied to estimate unadjusted and adjusted hazard ratio (HR) without
and with adjustment for other covariates, correspondingly.
The proportional hazards (PH) assumption underlying both
the log rank test and the Cox regression model was examined graphically and by statistical testing32 on the weighted
residuals.
The resultant KM curves crossed and thus, were in violation of the proportional hazard assumptions underlying
the log rank test and Cox regression model. Therefore, we
resorted to the restricted mean survival time (RMST, equivalently, t-year mean survival time) method33,34 to compare
the survival difference between TMZ administered in AM
versus PM. The RMST method quantifies the area under
the KM curve up to year t (specified by users) as a summary measure of survival. Intuitively, a greater area under
the KM curve and a greater RMST estimate indicates better
survival. We calculated the RMST-based difference of PM
relative to AM group to quantify the survival difference.
RMST does not depend on the proportional hazard assumption and serves as a more robust and widely applicable survival analysis approach. RMST modeling without
and with adjustment for covariates was performed at years
1–5. In the univariate RMST analysis, a negative RMST difference indicates worse survival in the PM group (better
survival in AM). In the multivariate RMST regression analysis, a negative coefficient estimate corresponds to better
survival in the AM group, adjusting for influence from
other covariates.
In consideration of existence of potential biases in observational data, we also evaluated the impact of TMZ timing
using the propensity score (PS) method35,36 as popularly
employed for observational studies. The propensity score,

Results
Patient Characteristics
A total of 180 patients were identified as de novo,
nonrecurrent GBM diagnosed at WUSM from January 1,
2010 to December 31, 2018. All patients underwent surgical
resection or biopsy followed by concurrent chemoradiation
therapy with TMZ, followed by maintenance TMZ. We
excluded 14 patients (Supplementary Figure 1: 11 with
IDH1/2-mutant secondary GBM, 2 with 1p/19q co-deleted
oligodendroglioma, and 1 with missing vital status). The remaining 166 patients were further evaluated for this study.
Patient demographic, tumor genomic, and clinical information are summarized in Table 1. The average age at
maintenance TMZ start was around 60 (IQR: 52.83–65.86)
years. More than 95% of the patients were Caucasian and
more than 60% were male. All the patients in the PM group
were seen by 1 physician (JC) while AM patients were seen
by 3 other physicians. The patient characteristics were all
similar between the AM and PM group, except for KPS and
enrollment rate in trials. KPS was higher in the PM group
(median = 90 vs 80 in AM group, P = 5.36E−10). 33 of the 89
AM patients and 5 out of the 77 PM patients had isocitrate
dehydrogenase (IDH) status missing (P = 1.89E−06). Nearly
70% of the patients in the AM group and 51% in the PM
group were enrolled in other clinical trials concurrent with
or after TMZ treatment (P = .017).

Increased Survival With Morning TMZ Revealed
by RMST Analysis
The median time to follow-up of the whole cohort of patients by the reverse KM method was 5.07 (95% CI: 4.29
to not reached [NR], range: 0.015–7.17) years. There were
145 deaths in the 166 patients during the study period.
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Statistical Analysis

that is, the likelihood of GBM patients receiving TMZ in the
PM versus AM, was modeled by a logistic regression with
all available baseline patient characteristics, including age
(continuous), sex (male vs female), extent of surgical resection (subtotal/biopsy vs gross total resection), MGMT promoter methylation status (methylated vs unmethylated),
Karnofsky performance status (KPS ≥80 vs <80), baseline
steroid use (Yes vs No), enrollment in DCVax-L clinical
trial (Yes vs No), and enrollment in other trials (Yes vs No),
and was subsequently predicted from this full logistic regression model. The Cox proportional hazard model was
applied to the PS-based inverse probability of treatment
(here, TMZ timing) weighting (IPTW) cohort and the PS
1:1 nearest neighbor matched cohort. For IPTW cohort, a
stable weight36 was calculated for each patient as inversely
proportional to the patients’ probability of receiving TMZ at
their designated time.
All the computation was conducted in R37 (version 3.6.1).
The R package “survRM2” 38 was used to perform the
RMST analyses. The R package “MatchIt” was used for PS
matching. All statistical tests were 2-sided unless otherwise noted. Statistical significance was claimed at the 5%
α level.

Neuro-Oncology
Advances

GBM oncologists consistently prescribed TMZ to be taken
on an empty stomach in the morning (AM), while 1 physician (J.C.) consistently prescribed TMZ to be taken in the
evening (PM). In the event that a patient preferred to take
TMZ at a time other than habitually prescribed, this was recorded in the patient record. Data on adverse events were
not collected on these patients during this retrospective
study. The study was approved by the institutional human
research protection office (HRPO#201507048).
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Table 1. Enrollment in Clinical Trials, IDH Status Missing Rate, and Karnofsky Performance Status Were the Only Characteristics That Differed
Between Groups. Patient and tumor characteristics summary, overall and by TMZ administration time (AM/PM)
All (N = 166)

AM (N = 89)

PM (N = 77)

P

60.1 (52.83–65.86)

59.28 (52.63–63.48)

61.65 (54.22–67.17)

.1623

Sex (N = 166)
Female
Male

.7476
61 (36.75)

34 (38.2)

27 (35.06)

105 (63.25)

55 (61.8)

50 (64.94)

Race (N = 166)
Black
Caucasian
KPS (N = 166)

1
6 (3.61)

3 (3.37)

3 (3.9)

160 (96.39)

86 (96.63)

74 (96.1)

80 (70–90)

80 (70–80)

90 (80–90)

KPS (N = 166)

5.36E-10
9.05E-07

KPS < 80

53 (31.93)

43 (48.31)

10 (12.99)

KPS ≥ 80

113 (68.07)

46 (51.69)

67 (87.01)

Bevacizumab Prior to TMZ (N = 166)

1

No

158 (95.18)

85 (95.51)

73 (94.81)

Yes

8 (4.82)

4 (4.49)

4 (5.19)

Bevacizumab concurrent with TMZ (N = 166)

.7258

No

158 (95.18)

84 (94.38)

74 (96.1)

Yes

8 (4.82)

5 (5.62)

3 (3.9)

Use of TTF (N = 166)

.1784

No

132 (79.52)

67 (75.28)

65 (84.42)

Yes

34 (20.48)

22 (24.72)

12 (15.58)

Enrolled in DCVax trial (N = 166)

.1733

No

151 (90.96)

78 (87.64)

73 (94.81)

Yes

15 (9.04)

11 (12.36)

4 (5.19)

No

65 (39.16)

27 (30.34)

38 (49.35)

Yes

101 (60.84)

62 (69.66)

39 (50.65)

GA

21 (12.65)

21 (23.6)

0 (0)

JC

80 (48.19)

3 (3.37)

77 (100)

Other clinical trial enrollment? (N = 166)

.0166

Physician (N = 166)

2.52E-44

GL

7 (4.22)

7 (7.87)

0 (0)

DT

58 (34.94)

58 (65.17)

0 (0)

IDH status*
WT
Missing

128 (77.1)

56 (62.9)

72 (93.5)

38 (22.9)

33 (37.1)

5 (6.5)

MGMT methylation (N = 151)

1

No

95 (62.91)

50 (63.29)

45 (62.5)

Yes

56 (37.09)

29 (36.71)

27 (37.5)

Biopsy

25 (15.15)

13 (14.77)

12 (15.58)

Gross total resection

93 (56.36)

49 (55.68)

44 (57.14)

Subtotal

47 (28.48)

26 (29.55)

21 (27.27)

No

161 (96.99)

87 (97.75)

74 (96.1)

Yes

5 (3.01)

2 (2.25)

3 (3.9)

164 (98.8)

89 (100)

Extent of surgical resection (N = 165)

.9524

Prior RT (N = 166)

.6638

Prior chemo (N = 166)
No

1.89E−06

.2137
75 (97.4)
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Continued

Variable (N)
Yes

All (N = 166)

AM (N = 89)

2 (1.2)

0 (0)

PM (N = 77)

.4364

No

78 (46.99)

39 (43.82)

39 (50.65)

Yes

88 (53.01)

50 (56.18)

38 (49.35)

Chemo/RT (N = 166)
Concurrent

.2494
163 (98.19)

86 (96.63)

77 (100)

3 (1.81)

3 (3.37)

0 (0)

Cycles of TMZ treatment (N = 166)

.8902
7.32 (3.76–13.85)

7.64 (3.79–13.04)

7.21 (3.75–14.36)

RT, radiation therapy; TMZ, temozolomide; TTF, tumor-treating fields.
Bold indicates significant P-values.
*Patients with IDH mutation have been excluded (see Supplementary Figure S1).
  

The median OS (95% CI) was estimated at 1.25 (95% CI:
1.09–1.56) years in the whole cohort (Figure 1A). The
1-year, 2-year, and 3-year OS probability was estimated
at 0.6 (0.53–0.68), 0.32 (0.26–0.4), and 0.17 (0.12–0.24), respectively. AM patients trended toward longer median OS
(median OS = 1.43, 95% CI: 1.12–1.92 years) than the PM
patients (median OS = 1.13, 95% CI: 0.84–1.58 years), but
the KM curves crossed near year 3 due to several longsurviving PM patients and their 95% CI overlapped (Figure
1B). Crossing KM curves violate the proportional hazard
assumptions of the log rank test and Cox regression
model, thus RMST was applied. From year 1 to year 5, the
AM group consistently had a higher RMST (areas under
the KM curve) compared to PM group and resulted in a
negative PM-AM RMST difference, indicating better OS in
AM group. When comparing all patients assigned to either
morning and evening TMZ dosing, the largest RMST difference was around −0.2 observed at year 3 but statistically
only reached significance in year 1 with a RMST difference
of −0.09 and 95% CI that did not cross 0 (Table 2).
When restricted to the 56 MGMT methylated patients,
the median OS was 6 months longer in the AM patients
(median OS = 2.13, 95% CI: 1.92–3.57 years vs 1.63, 95%
CI: 0.88–NR years in PM patients, Figure 1C). No significant difference was observed within the 95 unmethylated
patients (median OS = 1.06 in N = 29 AM patients vs
1.04 years in N = 27 PM patients, Figure 1D). Univariate
RMST difference analysis, when restricted to the MGMTmethylated patients, observed consistently negative coefficients through all the years with significant 95% CIs
at year 1 (−0.1304, 95 CI: −0.2419 to −0.019) to year 2.5
(−0.4323, 95% CI: −0.8365 to −0.0282). We further performed multivariate RMST difference regression analysis at year 1–5 accounting for the relevant confounders.
After the covariate adjustment, the negative coefficient
estimates for TMZ timing (PM minus AM) from the RMST
difference multivariate regression analyses indicated inferior OS at all the years for the PM group, both among
all the patients (Table 3) and in the MGMT-methylated
subset (Supplementary Table 4). Statistical significance
was reached at years 1, 2, and 5 (P = .014, .039, and .048,

respectively), marginally at year 3 (P = .07) but not at year
4 (P = .17) for all the patients (Table 3), while the resulting
P-values range from .099 to .3, likely due to small sample
size, in the MGMT-methylated subset (Supplementary
Table 4). The advantage of morning TMZ was even more
pronounced among the subsets of patients who were
older (N = 83, age at TMZ start ≥ 60 vs <60 years: median
OS = 1.28 vs 0.88 years, P = .15), enrolled in the DCVax-L
trial (N = 15, median OS = 2.32 vs 1.03 years, P = .041),
had bevacizumab (Avastin) concurrent with TMZ (N = 8,
median OS = 1.49 vs 0.88 years, P = .046), or did not enroll in other clinical trials (N = 65, median OS = 1.09 vs
0.74 years, P = .26; Supplementary Figure 2). The multivariate Cox modeling of the cohort with incorporation
of relevant covariates also indicated the trend of inferior OS in PM compared to AM (Supplementary Table 1,
HR = 1.22, 95% CI: 0.83–1.78), but the proportional hazard
test failed on the overall model globally (P = 5.94E−05)
and on TMZ timing alone (P = .015). In all the years’ multivariate RMST regression fittings, MGMT methylation
and extent of surgical resection remained highly significant while age, KPS, and enrollment in other trials also
were found significant on patient survival in most results
(Table 3).

Morning TMZ Remains Favorable After Adjusting
for Potential Study Bias
Considering potential biases in the observational study,
we modeled the likelihood of patients receiving TMZ in
PM versus AM using univariate (without covariates) and
multivariate logistic regression model adjusting for other
covariates. KPS, other trial enrollment, and DCVax-L trial
enrollment were found to potentially affect the likelihood
(Supplementary Table 2). Propensity score (PS) was calculated using the multivariate logistic regression to construct the IPTW weighting cohort and the PS matched (72
each in AM and PM) cohort. We subsequently performed
KM analyses and multivariate Cox regression analyses of
each cohort. The KM curves were like those of the original
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RT only

P

2 (2.6)
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A

  

All patients

1.0

B

AM(event/n:86/89,med=1.43,1.12~1.92
PM(event/n:59/77,med=1.13,0.84~1.58

Survival Probability

0.8

0.6

0.4

0.2

0.6

0.4

0.2

0.0 166
0

99

48

22

1

2

3
4
OS (years)

C

12

6

2

5

6

7

0

59
40

32
16

1

15
7

2

Survival Probability

0.6

0.4

2
0
6

7

AM(event/n:48/50,med=1.06,0.83~1.43
PM(event/n:36/45,med=1.04,0.72~1.41
P=0.850
HR=1.04 (0.67~1.61)

0.8

0.8

5
1

All patients
1.0

AM(event/n:28/29,med=2.13,1.92~3.57
PM(event/n:20/27,med=1.63,0.88~NA

8
4

3
4
5
OS (years)

D

MGMT methylated
1.0

89
77

0.0

0.6

0.4

0.2

0.2

29
27

0.0
0

26
15
1

16
11
2

10
4

6
3

3
4
OS (years)

3
1
5

2
0
6

29
27

0.0
7

0

26
15
1

16
11
2

10
4

3
OS (years)

6
3
4

3
1
5

Figure 1. Median overall survival in glioblastoma (GBM) patients tended to be longer in patients treated with temozolomide (TMZ) in the morning,
especially in MGMT-methylated patient subset. (A) Overall survival (OS) Kaplan–Meier (KM) curves of all (N = 166) patients with 95% confidence
band, (B) TMZ administration time (AM vs PM) among all patients, (C) TMZ administration among MGMT-methylated patients, (D) and among
MGMT-unmethylated patients. Indicated in the legend are event/n: total number of death/total number of patients, med: median OS with 95% CI, P:
log rank test P value; HR: Cox hazard ratio with 95% CI. Number of patients at risk from year 0 to 6 was indicated in each KM curve.
  

cohort, showing trends of worse OS in PM (Figure 2), with
KM curves still crossing around 3.5 years after diagnosis.
The multivariate Cox modeling of both cohorts yielded
similar results to the multivariate Cox modeling of the original cohort, but the proportional hazard assumption still
failed (Supplementary Table 3). Thus, after adjusting for differences in the likelihood of AM- and PM-treated patients
starting TMZ with different initial health scores or being enrolled in other clinical trials, we still observed the trend of
morning TMZ being associated with greater OS.

Discussion
In this study, we evaluated the impact of administering
TMZ in the morning versus in the evening on GBM patient
survival using data from our institution. We found morning
TMZ dosing associated with increased overall survival
in patients with MGMT methylated GBM even after accounting for potential biases in this retrospective analysis.
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Survival Probability

All patients

1.0

Event/n=145/166;med=1.25,95%CI:1.09~1.56

0.8

Survival Probability

6

  

0.2903
−0.4528 (−1.2919 to 0.3864)
1.7381 (1.3623–2.1139)
5

1.8289 (1.5594–2.0984)

−0.0908 (−0.5532 to 0.3717)

0.7004

2.1431 (1.4736–2.8126)

2.5958 (2.0899–3.1018)

0.1568
−0.4954 (−1.181 to 0.1903)
1.594 (1.2934–1.8945)
4

1.7553 (1.5192–1.9914)

−0.1613 (−0.5435 to 0.2209)

0.4082

1.9436 (1.4019–2.4853)

2.439 (2.0187–2.8592)

0.0360

0.0633

−0.4323 (−0.8365 to −0.0282)

−0.4678 (−0.9615 to 0.0258)

1.9639 (1.7332–2.1947)

2.1441 (1.8506–2.4375)
1.6762 (1.2793–2.0732)

1.5316 (1.1997–1.8634)
0.1149

0.1695
−0.2033 (−0.4932 to 0.0867)

−0.1968 (−0.4416 to 0.0479)
1.5193 (1.3604–1.6782)

1.6192 (1.4315–1.807)

1.3224 (1.1363–1.5086)

1.416 (1.195–1.637)

2.5

3

0.0218

0.0140

−0.1304 (−0.2419 to −0.019)

−0.3836 (−0.6897 to −0.0775)

0.9631 (0.9113–1.0149)

1.7222 (1.5554–1.889)
1.3386 (1.0819–1.5952)

0.8327 (0.734–0.9314)
0.0139

0.0763
−0.1735 (−0.3653 to 0.0183)

−0.09 (−0.1617 to −0.0183)
0.8894 (0.849–0.9298)

RMST difference
(PM–AM)
AM RMST

1.3707 (1.248–1.4934)

0.7994 (0.7401–0.8587)

1.1972 (1.0498–1.3447)

1

2

P value
RMST difference
(PM–AM)
PM RMST

AM RMST

MGMT-methylated Patients

PM RMST

P value
All Patients
Year

Downloaded from https://academic.oup.com/noa/article/3/1/vdab041/6156855 by Washington University, Law School Library user on 19 December 2022

The median OS of 15 months and the 5-year OS probability of 7% estimated from this cohort of patients were
comparable to previously reported studies such as Stupp
et al.3 (median OS = ~14.6 months, 5-year OS ~10%).The patients in the AM and PM groups were quite similar in terms
of age, race, sex, MGMT methylation, extent of surgical resection (which were found to be prognostic of survival as
known to the field), but KPS was found significantly higher
in the PM group. KPS is subjectively scored by treating
physicians and varies greatly as a result. The patients in
our AM cohort were seen by 3 physicians, whereas all the
patients in the PM group were seen by one physician. This
may have caused the KPS difference. We excluded all IDH
mutated patients but included all IDH wild type or missing
patients to maximize sample size. A greater percentage of
AM patients were missing IDH status than PM patients (33
out of 89 vs 5 out of 77), but the impact would be minimal
considering the lower IDH mutation rate ~10%.
We endeavored to additionally collect information on
trial enrollments in consideration of their potential impact
on survival. In our study, enrollment rate in the DCVax-L
trial (NCT00045968) and the use of TTF (NCT00916409) was
higher, albeit not statistically significant, in the PM group
(Table 1). More patients in the AM group enrolled in other
clinical trials (Table 1) after TMZ treatment. The other clinical trials in our study included NCT00884741 (radiation
and TMZ with or without bevacizumab), NCT01062425
(radiation and TMZ with or without cediranib maleate),
NCT01480479 (ACT IV: Adjuvant TMZ with or without
rindopepimut), NCT00869401 (radiation and TMZ with or
without dasatinib), NCT02179086 (TMZ and standard radiation or photon intensity-modulated radiation therapy),
NCT00770471 (ABT-888: TMZ and radiation with or without
veliparib), and NCT02667587 (CheckMate548: TMZ and radiation with or without nivolumab), each with fewer than
5 patients. Subset analysis observed in AM TMZ a trend toward higher (albeit statistically not significant) median OS
(median OS, 95% CI = 1.09, 0.73–2.6 in AM vs 0.74, 0.6–1.95
in PM) in the subset of N = 65 patients who did not enroll in these other clinical trials, while similar survival to
PM TMZ among those who enrolled in these other trials
(Supplementary Figure S2). After adjusting for the known
GBM prognostic factors (age, MGMT methylation, extent
of surgery) and trial enrollment in DCVax-L, TTF, and others,
the advantageous OS was observed in the AM group based
on the multivariate RMST difference regression analyses
at years 1, 2, and 5 (all P < .05).
GBM is a fatal disease and no new drugs have been
approved in over a decade. Critical thinking is needed
to further improve GBM patient management and survival outcome. Changing time of administration of TMZ
would be cost-effective and easy to adjust to for patients.
We found that TMZ administration timing impacted patient survival overall and had a greater effect in MGMTmethylated GBM patients. This is consistent with previous
studies showing that MGMT silencing confers a better
response to TMZ treatment.2,39–42 Based on the overall
2.5-month and MGMT-methylated 6.4-month median OS
improvement by concomitant TMZ with radiation from
Stupp et al. and companion translational study from
Hegi et al.2,3 (NCT00006353), the concomitant treatment
regimen has become standard clinical practice. In our
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Table 2. AM Treatment Significantly Improved Treatment Using Univariate RMST Analysis in Year 1 for All Patients and Year 1–2.5 for MGMT-methylated Patients. Univariate RMST analysis for OS was performed at year 1–5, estimating RMST for PM and AM and comparing PM and AM based on RMST difference (PM–AM), accompanied with 95% CI (nonoverlapping with 0 indicating significant difference), for all
patients and MGMT-methylated patients
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−0.086
(−0.155,−0.017)

0.02
(−0.046,0.086)

−0.002
(−0.005,0)

0.156
(0.089,0.222)

0.059
(−0.017,0.134)

0.126
(0.058,0.194)

−0.052
(−0.121,0.016)

−0.023
(−0.107,0.061)

0.039
(−0.053,0.131)

0.174
(0.1,0.247)

TMZ timing (PM vs AM)

Sex (Male vs Female)

age at TMZ start (continuous)

MGMT methylation (Yes vs No)

KPS (≥80 vs <80)

Extent of Surgical Resection (gross
total resection vs subtotal/biopsy)

Baseline steroid Use (Yes vs No)

Novocure Optune Use (Yes vs No)

DCVax Trial enrollment (Yes vs No)

other Trial enrollment (Yes. vs No)

  

3.36E−06

.405

.588

.135

.000

.129

4.53E−06

.090

.556

.014

8.16E−13

0.39
(0.217,0.564)

0.24
(−0.011,0.491)

0.002
(−0.228,0.231)

−0.059
(−0.243,0.125)

0.269
(0.102,0.435)

0.176
(−0.042,0.393)

0.626
(0.442,0.811)

−0.008
(−0.015,−0.001)

−0.022
(−0.202,0.159)

−0.196
(−0.382,−0.01)

1.093
(0.586,1.599)

1.03E−05

.060

.989

.530

.002

.114

2.71E−11

.031

.813

.039

2.36E−05

P value

Year 3

0.548
(0.254,0.842)

0.309
(−0.146,0.764)

−0.12
(−0.441,0.201)

0.019
(−0.297,0.335)

0.494
(0.229,0.759)

0.269
(−0.083,0.622)

0.912
(0.613,1.211)

−0.015
(−0.027,−0.003)

−0.005
(−0.275,0.266)

−0.263
(−0.547,0.021)

1.322
(0.47,2.174)

Regression
coefficient
(95% CI)

.0003

.1836

.4643

.9045

.0003

.1341

2.2E−09

.0147

.9735

.0692

.0024

P value

Year 4

0.448
(−0.049,0.946)

0.34
(−0.289,0.97)

−0.214
(−0.607,0.178)

0.014
(−0.513,0.54)

0.652
(0.243,1.06)

0.274
(−0.296,0.845)

1.274
(0.821,1.727)

−0.019
(−0.035,−0.004)

0.093
(−0.293,0.478)

−0.27
(−0.653,0.112)

1.517
(0.42,2.614)

Regression
coefficient
(95% CI)

.077

.289

.285

.960

.002

.346

3.59E−08

.015

.637

.166

.007

P value

.048
.260
.015

−0.422
(−0.841,−0.004)
−0.285
(−0.781,0.211)
−0.026
(−0.047,−0.005)

.005
.462
.391
.279
.179

0.174
(−0.29,0.638)
−0.181
(−0.596,0.233)
0.416
(−0.337,1.169)
0.31
(−0.142,0.763)

.020
0.696
(0.207,1.186)

0.542
(0.086,0.998)

2.99E−08

.004

1.942
(0.625,3.259)

1.603
(1.036,2.17)

P value

Year 5
Regression
coefficient
(95% CI)
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Bold indicates significant P-values.

0.751
(0.546,0.957)

Year 2
Regression
coefficient
(95% CI)

P value

Year 1

Regression
coefficient
(95% CI)

intercept

Terms

  
Table 3. AM Treatment Significantly Improved Treatment in Years 1, 2, and 5 Using Multivariate RMST Analysis Among All the Patients. Multivariate OS RMST regression for RMST difference (PM–AM) was
performed at year 1–5, adjusting for covariates (as listed in the table) among all the patients. Regression coefficients with 95% CIs and P values were reported. A negative coefficient indicates worse survival of
PM versus AM
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1.0

1.0

PS IPTW: AM
PS IPTW: PM
HR (95% CI)=1.3 (0.87~1.93)
Cox P=0.2

0.4

0.6

0.4

0.2

0.2

0.0

0.0
0

1

2

3

4

5

6

PS matched: AM
PS matched: PM
HR (95% CI)=1.12 (0.78~1.6)
Cox P=0.53

0.8
Survival Probability

0.6

Original: AM
Original: PM

7

OS (years)

0

1

2

3

4

5

6

OS (years)

Figure 2. Patient survival tended to be longer with morning temozolomide (TMZ) treatment after correcting for potential biases in patient recruitment. Kaplan–Meier (KM) curves of TMZ timing (PM: solid line; AM: dashed line) in (A) propensity score (PS)-based inverse probability of treatment
weighting (IPTW) cohort and (B) PS-matched cohort (both in red), overlaid on the KM curves of the original study cohort (in black).
  

study, maintenance TMZ administered in AM improved
the median OS by 6 months in MGMT-methylated patients (with significant 95% RMST difference CIs at years
1 to 2.5) without the need of adding another therapy. On
the other hand, TMZ timing had no impact on survival in
MGMT-unmethylated GBM patients. These observations
conform to our predictions. MGMT-unmethylated patients
are generally resistant to adjuvant TMZ treatment and the
mechanism of resistance is not expected to be altered by
changing the timing of TMZ administration. However, in
the more responsive, MGMT-methylated, GBM patients, it
appears that response can be further optimized by timed
treatment.
This work demonstrates the potentially powerful impact of TMZ chronotherapy in GBM. Given that TMZ rapidly
absorbed, reaching peak levels in plasma within 1h after
oral dosing, and is spontaneously degraded at physiological pH, with a half-life of 1.8 h, precise dose timing is possible.31,43 This is key in bringing TMZ chronotherapy to the
clinic, as preclinical studies have shown maximal TMZ efficacy during a 6-h window of treatment corresponding to
the peak of core clock protein BMAL1,16 which peaks just
before dawn in several human tissues.44,45 Morning timing
may be the most effective in humans due to daily fluctuation in absorption and excretion of the drug, as well as
the sensitivity of tumor cells to DNA damage.24,46,47 TMZ
chronotherapy also has potential to be customized to the
patient’s unique circadian rhythm. We observed that AM
TMZ may improve survival in patients over 60 years old.
Older patients tend to be earlier chronotypes,48 starting
their daily activity earlier, and TMZ taken in the morning
better conformed to this circadian pattern and, thus, exerted a greater efficacy. Future studies should incorporate

the established effects of chronotype on therapeutic responses.49 Such studies are needed to explore these potential mechanisms and to determine if peripheral clock
gene expression can determine optimal dosing time for
individuals.
The KM curves of AM and PM crossed over and the proportional hazard assumption failed mostly. This was attributable to 6 outlier patients who were alive with long OS
(>3 years) in the PM group. All 6 of the patients (3 male, 3
female) had gross total resection, none were IDH1/2 mutated, and 3 of them were MGMT methylated. PS-based
survival analyses showed similar results to the original
cohort analyses and violation of the proportional hazard
assumption was similarly observed. Thus, we resorted to
the RMST method which does not rely on the proportional
hazard assumption and the multivariate RMST analyses
found that TMZ in AM was superior to PM TMZ at years 1, 2,
and 5 after adjusting for confounders.
As the very first paper exploring the TMZ chronotherapy effect in GBM, the study has various limitations.
Due to its retrospective nature, the study may harbor potential issues (such as selection bias) which are common
in observational studies. To address this, we have employed the PS-based methods (including IPTW and PS
matching), which yielded results consistent with the survival analyses of the original cohort. While this is the largest patient cohort in this line of research, the sample size
of the study was still moderate and thus was insufficient
to detect the relatively small effect of TMZ chronotherapy
in some analyses. Note that most current treatments result in modest improvement in GBM patient outcomes.
GBM patient survival can be impacted by many factors.
We have considered major demographical and clinical
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factors, and even clinical trial participation. However,
confounders that were not collected/recorded could not
be accounted for. The patient population was primarily
Caucasian, thus findings from this study may not generalize to non-Caucasian patient populations. The AM/PM
TMZ grouping was based on the treating physicians’ habitual prescription as stated in the Methods section. We
assumed that patients in this cohort complied with the
designated TMZ administration timing as prescribed by
the treating physicians, although the compliance cannot
be controlled in this retrospective study. Finally, we focused on the impact of TMZ timing on patient survival and
did not collect side effect data in this study. We acknowledge that toxicity profiles may differ as a consequence of
AM versus PM TMZ dosing. This should be prospectively
evaluated.
Future large retrospective studies at other institutions
and prospective randomized controlled trials are required
to further validate our findings on the TMZ chronotherapy
effect in GBM patients. A randomized 2-arm phase II trial
(NCT02781792) where 30 brain tumor patients are randomized
at 1:1 ratio to receive TMZ in the morning (before 10 AM) or in
the evening (after 8 PM) is ongoing. This trial will examine adverse events in addition to patient survival. If our findings can
be replicated in this and other studies,TMZ chronotherapy can
be easily and immediately implemented without fundamentally altering the current standard of care and may improve
anti-tumor efficacy in GBM patients. More broadly, chronotherapy is a growing field with potential to improve outcomes
in many cancer types and diseases beyond cancer.
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